marked.bio

anti-EGFR antibody · antibody

panitumumab

14 active trials across 5 of our biomarkers, targeting EGFR. 1 active approval for a biomarker on marked.bio.

Also known as ABX-EGF, Vectibix.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Approvals and pivotal results

Biomarker-selected approvals in the United States and the European Union, with the pivotal trial's results and side effects where we have them. Results from different trials are not directly comparable.

TherapyBiomarkerTumourUnited StatesEuropean Union
sotorasib with panitumumab
FDA, 2025
metastatic, after fluoropyrimidine/oxaliplatin/irinotecan chemotherapy FDA approval 16/01/2025 (regular; no accelerated-approval statement on the current label). Source
Lumakrassotorasib page 		KRAS G12C colorectal Approved 2025 Not approved

CodeBreaK 300 vs trifluridine/tipiracil or regorafenib (investigator's choice), 53 vs 54 patients
PFS 5.6 months vs 2.0 months, HR 0.48 (0.30-0.78)Response 26% vs 0%OS not reached vs 10.3 months, HR 0.70 (0.41-1.18), not significant

Serious side effects 26%Stopped for side effects 2% (1 patient)Fatal 4.3%

Trial details and side effects
Patients
KRAS G12C metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan (NCT05198934)
Most common side effects
rash 87%, dry skin 28%, diarrhoea 28%, stomatitis 26%, fatigue 21%, musculoskeletal pain 21% (47 patients)
Notes
US label rev. 01/2025, sections 6 and 14. Sotorasib 960 mg with panitumumab.
Source
US label

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 9 17 Phase 3
KRAS G12D 6 12 Phase 2
BRAF V600E 2 7 Phase 2
BRCA1/2 mutation 1 1 Phase 3
MSI-H / dMMR 1 2 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of panitumumab.

  1. Amgen 3
  2. Verastem 2
  3. Astellas 1
  4. Roche 1

Trials

14 of 27 trials shown

  1. Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

    Recruiting Phase 3 SWOG Cancer Research Network Started 2026Primary completion 2029-12 NCT06998940

    fluorouracilgemcitabineirinotecanliposomal irinotecanleucovorinnab-paclitaxelpaclitaxelpanitumumab

    Prior maintenance therapy with Olaparib or Rucaparib for germline or somatic BRCA1/2 or PALB2 mutations does not count as a line of therapy.

    BRCA1/2 mutationLocally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8

  2. Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

    Recruiting Phase 3 Amgen Started 2024Primary completion 2028-09 NCT06252649

    FOLFIRIsotorasib FDA EUpanitumumab FDAbevacizumab

    Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.

    KRAS G12CMetastatic Colorectal Cancer

  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07659795

    VS-7375cetuximabpanitumumabmFOLFOX6

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    KRAS G12DColorectal Cancer

  4. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    Recruiting Phase 2 Verastem Started 2026Primary completion 2027-06 NCT07644559

    VS-7375cetuximabpanitumumab

    Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)

    KRAS G12DPancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS

  5. 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

    Not yet recruiting Phase 2 Federation Francophone de Cancerologie Digestive Started 2025Primary completion 2030-06 NCT07124884

    sotorasib FDA EUpanitumumab FDAfluorouracil

    Proven KRAS G12C mutation as locally assessed by means of an IVDR-compliant test

    KRAS G12CColorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer

  6. A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

    Recruiting Phase 2 Blokhin's Russian Cancer Research Center Started 2025Primary completion 2027-11 NCT06978400

    mFOLFOX6dabrafenib FDA EUcetuximab FDA EUpanitumumab

    Histologically confirmed colorectal adenocarcinoma that contains MSS and BRAF V600E mutation

    BRAF V600ENeoplasms

  7. Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2024Primary completion 2028-12 NCT05638295

    panitumumab FDAsotorasib FDA EU

    Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment

    KRAS G12CAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm

  8. Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

    Recruiting Phase 2 Gruppo Oncologico del Nord-Ovest Started 2023Primary completion 2027-05 NCT05845450

    trastuzumab deruxtecandurvalumabpanitumumab FDAbotensilimabbalstilimabsotorasib FDA EUVorbipiprantnivolumabamivantamab

    COHORT 8: pMMR/MSS status and KRAS G12C mutation, absence of HER2 overexpression/amplification and wild-type status for BRAF.

    KRAS G12CMSI-H / dMMRColorectal Cancer, Resectable Colorectal Carcinoma

  9. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    Recruiting Phase 1/2 Institut de Recherches Internationales Servier Started 2023Primary completion 2028-06 NCT05786924

    S241656FOLFOX6/FOLFOX7FOLFIRIcetuximabpanitumumab FDAgemcitabinenab-paclitaxel

    Part 2A4: Advanced/metastatic NSCLC with a KRAS G12C mutation

    KRAS G12CBRAF V600ENon-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation

  10. Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017Primary completion 2027-01 NCT03087071

    panitumumab FDAtrametinib

    may have a concomitant mutation in KRAS, NRAS, or BRAF, if there is at least a 5-fold higher allele frequency of the most prevale…

    KRAS G12CKRAS G12DEGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma

  11. A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma

    Not yet recruiting Phase 1 Roche Started 2026Primary completion 2029-03 NCT07859085

    GDC-7035panitumumabmFOLFOX6FOLFIRImFOLFIRINOXGem-nabP

    Confirmed presence of the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutation as documented through central laboratory testing or prior local laboratory testi…

    KRAS G12DColorectal Neoplasms, Pancreatic Ductal Adenocarcinoma

  12. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Recruiting Phase 1 Astellas Started 2025Primary completion 2028-11 NCT07094204

    ASP5834panitumumab FDA

    …alignancy with a documented Kirsten rat sarcoma viral oncogene homolog (KRAS) G12V, G12D, G12C, G12R, G12A or G13D mutation or KRAS amplification (copy number \>/= 4) determined by loc…

    KRAS G12CKRAS G12DSolid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

  13. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    Recruiting Phase 1 Amgen Started 2025Primary completion 2028-04 NCT07094113

    AMG 410pembrolizumabpanitumumab FDA

    Pathologically documented, locally-advanced or metastatic malignancy with any missense mutation in the KRAS gene or evidence of KRAS amplification using an analytically validated KRASWT amplificati…

    KRAS G12CKRAS G12DKRAS Altered Advanced or Metastatic Solid Tumors

  14. Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    Active, not recruiting Phase 1 Amgen Started 2019Primary completion 2026-12 NCT04185883

    sotorasib FDA EUtrametinibvociprotafibafatinibpembrolizumabpanitumumab FDAcarboplatinpemetrexeddocetaxelpaclitaxelatezolizumabpalbociclib

    Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requireme…

    KRAS G12CAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation